Bendamustine

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2124 publications

Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma

Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Synchronous Follicular Lymphoma and Lung Adenocarcinoma-A Case Report

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report.

Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report.

Journal: Cureus

Published: July 29, 2026

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

Journal: Cancers

Published: July 08, 2026

Aggressive non-nodal mantle cell lymphoma with challenging subtype classification at presentation

Aggressive non-nodal mantle cell lymphoma with challenging subtype classification at presentation

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 08, 2026

Bendamustine in indolent lymphoma: Letting the dust settle down.

Bendamustine in indolent lymphoma: Letting the dust settle down.

Journal: Cancer

Published: July 07, 2026

Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors

Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 06, 2026

Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".

Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".

Journal: Haematologica

Published: July 01, 2026

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: June 27, 2026

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility.

BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility.

Journal: Medicina (Kaunas, Lithuania)

Published: June 25, 2026

Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma.

Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma.

Journal: Journal of medicinal chemistry

Published: June 24, 2026

A Dual Response to CD20xCD3 Bispecific Therapy: Remission of Relapsed Diffuse Large B-cell Lymphoma and Improvement in Immune Thrombocytopenia.

A Dual Response to CD20xCD3 Bispecific Therapy: Remission of Relapsed Diffuse Large B-cell Lymphoma and Improvement in Immune Thrombocytopenia.

Journal: Cureus

Published: June 18, 2026

Showing 1-12 of 2,124

Last Updated: 09/26/2026